News

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Oak Ridge, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement…

1 year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by…

1 year ago

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform…

1 year ago

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies,…

1 year ago

Aeroflow Health Launches Venture Arm; Co-Leads $3.7 Million Seed Round for Canopie

ASHEVILLE, N.C., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support…

1 year ago

HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health

NAPLES, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology,…

1 year ago

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

- New U.S. patent covers the design and composition of the BVP - - Positive results from ongoing preclinical studies…

1 year ago

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination…

1 year ago

CorMedix Inc. Announces New Commercial Agreement

BERKELEY HEIGHTS, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic…

1 year ago

LifeMD Announces Major Enhancements to its Weight Management Program, Expanding Patient Access to Branded GLP-1 Therapies and Introducing New Treatment Options

Investments in pharmacy benefits infrastructure, in-home lab services and new treatment options expand platform capabilities and are estimated to increase…

1 year ago